"Qualifying companies for Pipelines of Promise are biotechnology-focused companies that have at least started some human trials."

Yes, Resverlogix has "started some human trials." However, they have all been with one molecule RVX-208/apabetalone. Where is the "pipeline" for Resverlogix and is it "promising?" Resverlogix needs to do a better job at promoting their promising pipeline if they expect current and future investors to get excited about it. The current website and clinical trials are all about one single molecule. Where is the pipeline?

Yes, they have the BET platform with thousands of compounds and various filed patents. But the Resverlogix website goes into zero additional detail on other pre-clinical compounds and their potential indications. It sure would be nice for Resverlogix to promote their "pipeline" better. 

From the September 2016 R&R webcast October 2016 R&D update: 2400 synthesized compounds in library. Seven compounds were chosen for follow-on testing. RVX-206, RVX-641, RVX-2101, RVX-2113 just happen to be 4 of DM’s favorites. They confirmed a second clinical compound IND candidate, though I'm not sure if the IND has been filed. They will be working with various indications in parallel. 

The above info should be better advertised on the RVX website to better educate current and new investors about the "pipeline".

BearDownAZ